About Breast Cancer mAbs

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

Technavio’s analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Amgen
• Roche
• Mylan

Other prominent vendors
• Array BioPharma
• AstraZeneca
• Biocad
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celldex Therapeutics
• Celltrion
• Chugai Pharmaceutical
• Daiichi Sankyo
• DARA Biosciences
• Eddingpharm
• Eisai
• Galena Biopharma
• GlaxoSmithKline
• Halozyme Therapeutics
• Hospira
• ImmunoGen
• Immunomedics
• MacroGenics
• Merck
• Novartis
• Oncothyreon
• Pfizer
• ProStrakan
• Puma Biotechnology
• Seattle Genetics
• Sun Pharmaceutical Industries
• Synta Pharmaceuticals
• Teva Pharmaceuticals

Market driver
• Reimbursement benefits for breast cancer mAbs
• For a full, detailed list, view our report

Market challenge
• Absence of adequate diagnosis and screening procedures for early detection
• For a full, detailed list, view our report

Market trend
• Emergence of targeted and combination therapies for breast cancer
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.